Cole G Bradley sold $299K of KNSA
Cole G Bradley sold 3,673 shares of Kiniksa Pharmaceuticals International, plc (KNSA) at $81.43 ($0.30M total) on 2026-07-29.
How this was made
The 30-second read
Why it matters
The only new information is the director’s open-market sale details (shares, price, total value, and remaining holdings).
Market read
Traders may note insider selling as a sentiment datapoint, but there is no accompanying company-specific catalyst in the filing.
What to watch
The article lacks context on total holdings, prior sale cadence, tax/option exercises, and whether other insiders sold or bought around the same period.
Background
The article is an SEC Form 4 insider transaction disclosure for Kiniksa Pharmaceuticals International, plc.
Ticker impact
Kiniksa Pharmaceuticals director Cole G. Bradley sold 3,673 shares on 2026-07-29 for about $299,092, per a new SEC Form 4.
Likely limited near-term impact; any effect is more sentiment-driven than fundamental.
The filing provides transaction size, price, and post-sale holdings, but no new operational, regulatory, or financial information about KNSA.
Market effects
Minimal; insider sale does not change sector outlook for biotech/pharma in this text.
None indicated.
None indicated.
Counterpoint
Insider sales can be planned for diversification or liquidity needs; the absence of a stated 10b5-1 plan does not necessarily imply negative expectations.
Key entities
- issuerKiniksa Pharmaceuticals International, plc
Subject of the Form 4 insider transaction disclosure.
- insiderCole G Bradley
Director who sold 3,673 shares at $81.43 on 2026-07-29.
